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The pathological accumulation of RNA-binding proteins (RBPs) within inclusion bodies is a hallmark of
amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). RBP aggregation re-
sults in both toxic gain and loss of normal function. Determining the protein binding partners and
normal functions of disease-associated RBPs is necessary to fully understand molecular mechanisms of
RBPs in disease. Herein, we characterized the protein–protein interactions (PPIs) of RBM45, a RBP that
localizes to inclusions in ALS/FTLD. Using immunoprecipitation coupled to mass spectrometry (IP–MS),
we identiﬁed 132 proteins that speciﬁcally interact with RBM45 within HEK293 cells. Select PPIs were
validated by immunoblot and immunocytochemistry, demonstrating that RBM45 associates with a
number of other RBPs primarily via RNA-dependent interactions in the nucleus. Analysis of the biological
processes and pathways associated with RBM45-interacting proteins indicates enrichment for nuclear
RNA processing/splicing via association with hnRNP proteins and cytoplasmic RNA translation via eiF2
and eiF4 pathways. Moreover, several other ALS-linked RBPs, including TDP-43, FUS, Matrin-3, and
hnRNP-A1, interact with RBM45, consistent with prior observations of these proteins within intracellular
inclusions in ALS/FTLD. Taken together, our results deﬁne a PPI network for RBM45, suggest novel
functions for this protein, and provide new insights into the contributions of RBM45 to neurodegen-
eration in ALS/FTLD.
This article is part of a Special Issue entitled SI:RNA Metabolism in Disease.
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The aggregation of RNA-binding proteins (RBPs) into inclusion
bodies is one of the most prevalent and well-characterized pa-
thological ﬁndings in amyotrophic lateral sclerosis (ALS) and
frontotemporal lobar degeneration (FTLD). The identiﬁcation of
cytoplasmic mis-localized TDP-43 (Neumann et al., 2006), and
later FUS (Kwiatkowski et al., 2009; Vance et al., 2009), as primary
components of ubiquitinated inclusions in motor neurons and glia
in these disorders led to the “two-hit” hypothesis of RBP-mediated
neurodegeneration. This model proposes that the pathological
aggregation of RBPs confers toxicity by simultaneous gain of toxic
function of the aggregates and the loss of normal functions served
by these proteins in regulating gene expression. Ample experi-
mental evidence now exists in support of this model, with studies
consistently ﬁnding that under- or overexpression of numerous
RBPs is sufﬁcient to induce neuronal cell death in a variety of
model systems (reviewed in Ling et al. (2013)).
This model of RBP-mediated neurodegeneration depends, in
part, on the ability of RBPs to self-associate and interact with other
RBPs within protein aggregates. Many ALS-linked RBPs, including
TDP-43, FUS, hnRNP-A1, and TAF15 are aggregation prone as a
result of prion-like domains contained within their protein se-
quence (Johnson et al., 2009; King et al., 2012). Mutations in the
prion-like domain lead to familial forms of ALS/FTLD marked by
the pathological aggregation of the mutant protein (reviewed
in Gitler and Shorter (2011)). In addition to self-aggregation, these
proteins are capable of sequestering other proteins into ag-
gregates/inclusions as a consequence of the normal functional
associations between these proteins. For example, proteomic
analysis of TDP-43 aggregates showed deposition of stress granule
proteins G3BP and PABPC1 as well as paraspeckle proteins PSF and
NONO (Dammer et al., 2012). Similar observations of paraspeckle
proteins p54nrb and NONO in FUS-positive inclusions (Shelk-
ovnikova et al., 2014) provide additional evidence in support of
this concept. Thus, understanding the protein–protein interactions
(PPIs) of ALS-linked RBPs is a necessary step towards deﬁning the
protein composition of inclusions in ALS/FTLD and new insight
into mechanisms of disease.
Determining RBP PPIs is also essential for understanding the
normal functions of RBPs, and how these functions may be com-
promised as a result of RBP aggregation in ALS/FTLD. Numerous
RBP functions depend on the association of RBPs with protein/
nucleic acid complexes. For example, FUS is a component of both
nuclear gems, which participate in snRNP biogenesis, and para-
speckles, which are involved in cellular stress responses (Shelk-
ovnikova et al., 2014; Yamazaki et al., 2012). The expression of
mutant FUS reduces levels of these nuclear sub-structures, sug-
gesting mechanisms by which loss of normal FUS function con-
tributes to cell death in ALS/FTLD. In addition, many ALS/FTLD-
linked RBPs also associate with cytoplasmic stress granules (Li
et al., 2013), and disease-associated mutations tend to promote theexcess formation of these structures (Kim et al., 2013). While stress
granules normally aid in the response to cellular stress by pro-
tecting mRNAs and shifting gene expression towards a stress re-
sponse, excessive stress granule formation promotes the formation
of insoluble RBP aggregates that may be precursors to inclusion
bodies (Kim et al., 2013; Li et al., 2013; Vance et al., 2013). This can
lead to loss of other normal functions, such as impaired P-body
formation that occurs in response to mutant FUS sequestration in
stress granules (Takanashi and Yamaguchi, 2014). PPIs can be used
to predict these and similar functional associations (Dammer et al.,
2012). Deﬁning RBP PPIs, therefore, helps uncover novel functions
and candidate disease mechanisms related to these multi-
functional proteins.
Given the diversity of RBP functions, which includes regulating
transcription, RNA splicing/export, and miRNA biogenesis (Ling
et al., 2013), a relatively high-throughput approach is preferable to
identify candidate functions/binding partners for targeted valida-
tion. Immunoprecipitation coupled to mass spectrometry (IP–MS)
offers tremendous promise towards identifying large sets of RBP
protein–protein interactions (PPIs) and associated biological pro-
cesses/pathways. The sensitivity of this approach can be further
enhanced by the use of cross-linking methods, such as treatment
with small cross-linking agents or formaldehyde, to detect low-
afﬁnity protein interactions (Li et al., 2015; Nittis et al., 2010). This
approach has previously been used to identify proteins interacting
with the ALS-linked Ewing Sarcoma (EWS) RBP (Pahlich et al.,
2009), where interactions with hnRNPs and FUS are consistent
with roles of EWS in mRNA splicing (Law et al., 2006) and inclu-
sion formation in ALS/FTLD (Mackenzie and Neumann, 2012), re-
spectively. Thus, IP–MS can identify multiple protein binding
partners of a given target and this information can be used to
predict novel functions and roles in disease.
Here, we applied this approach to RBM45, a recently char-
acterized RNA-binding protein found in inclusions in ALS, FTLD,
and Alzheimer's disease (AD) (Collins et al., 2012). These inclusions
are positive for TDP-43, and RBM45 physically interacts with TDP-
43 and FUS in vitro (Li et al., 2015). RBM45 contains three RNA-
recognition motifs (RRMs), a nuclear localization sequence (NLS),
and a homo-oligomerization (HOA) domain that mediates self-
association of the protein, and can localize to cytoplasmic stress
granules (Bakkar et al., 2015; Li et al., 2015). The expression of
RBM45 is developmentally regulated and the highest expression
levels occur in the brain (Tamada et al., 2002). These properties
make RBM45 a promising target for continued studies of ALS/
FTLD, though at present little is known about the function of
RBM45. To delineate protein binding partners of RBM45 and pu-
tative biological functions of the protein, we used an IP–MS ap-
proach to comprehensively characterize RBM45 protein–protein
interactions (PPIs). We identiﬁed 132 RBM45 PPIs by IP–MS, in-
cluding PPIs with many RBPs. Our results were used to associate
RBM45 with biological processes and pathways. These were pri-
marily related to nuclear mRNA processing and cytoplasmic RNA
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with a number of ALS-linked proteins, including TDP-43, FUS,
Matrin-3, hnRNP-A1, and hnRNP-A2/B1. Selected PPIs were ex-
ternally validated via complementary techniques. Collectively, our
results shed new light on RBM45 PPIs, biological functions, and
contributions to neurodegeneration in ALS/FTLD.2. Results
2.1. Identiﬁcation of the RBM45 interacting proteins in HEK-293 cells
A schematic outline of the immunoprecipitation–mass spec-
trometry procedure used in this study is shown in Fig. 1A. FLAG-
RBM45 or empty vector was overexpressed in HEK293 cells and
immunoprecipitated using whole cell lysates in triplicates. HA-
tagged RBM45 was also included and used as a reference for the
data analysis. HEK293 cells expressing empty vector alone served
as negative controls. Regular IP and formaldehyde crosslinking IP
were performed in parallel to identify strongly and weakly
RBM45-associated proteins separately (Fig. 1A). Immunoblot ana-
lysis of the immunoprecipitated fractions showed that tagged-Fig. 1. Identiﬁcation of RBM45 interacting proteins. (A) Diagram of the immunoprecip
(B) Triplicate immunoprecipitates from HEK293 cells stably expressing FLAG-RBM45, HA
blue to visualize proteins. Immunoprecipitations with FLAG (sample 1, 2, 3, 4), HA (sampl
regular IP (sample 3, 4, 5) were performed in parallel. For crosslinking IP, live cells w
immunoprecipitation. The crosslinking was reversed by heating in SDS-sample buffer
(excluding the IgG-heavy chain and IgG-light chain that are denoted by red *) and an
interacting proteins. (For interpretation of the references to color in this ﬁgure legend,RBM45 was enriched in the pulldown. In contrast, no RBM45 was
detected in the pulldown in the vector control or IgG pulldown
(Supplemental Fig. 1). These data demonstrate that tagged-RBM45
can be efﬁciently and speciﬁcally immunoprecipitated from cell
extracts. Co-immunoprecipitated proteins were then separated
using SDS-PAGE and stained (Fig. 1B). Coomassie staining of the
gels loaded with RBM45-IP (sample 1, 3 and 5) identiﬁed several
bands that were not present in vector (sample 2 and 4) or IgG
controls (sample 6 and 7).
Immunoprecipitated proteins were gel extracted, trypsin di-
gested, and identiﬁed by liquid chromatography tandem mass
spectroscopy (LC-MS/MS) (Fig. 1A, see Section 4). We identiﬁed
235 unique proteins with a protein False Discovery Rate equal or
lower than 1%. We then applied a manual thresholding approach
and a probabilistic PPI prediction algorithm (SAINTexpress) to
compute the most likely associations between each of these 235
proteins and RBM45, yielding 132 high-conﬁdence candidates
(Fig. 1A). These 132 candidate proteins were found in at least 2 out
of the 3 FLAG-IP triplicates and were at least 2-fold more abundant
compared to vector control, suggesting that they speciﬁcally as-
sociate with RBM45 (Table 1 and Supplemental Tables 1–3). Of
these 132 proteins, 28 were found exclusively by regular-IPitation–mass spectrometry approach to identify the RBM45 interacting proteins.
-RBM45 or empty vector were separated by SDS-PAGE and stained with Coomassie
e 5) antibody or IgG (sample 6, 7) were performed. Crosslinking IP (sample 1, 2) and
ere treated with 0.1% formaldehyde to cross-link proteins prior to cell lysis and
prior to SDS-PAGE. The proteins along the entire length of the gel were extracted
alyzed by LC/MS–MS. (C) Pie-chart representation of functional classes of RBM45
the reader is referred to the web version of this article.)
Table 1
Merged list of identiﬁed RBM45 interacting proteins from manual analysis and SAINTexpress algorithma.
Proteins Spectral count sum Fold spectra increase AvgP Canonical pathway
Manual SAINTexpress SAINTexpress EIF2 eIF4/p70S6K mTOR Telomere Ext. RAN
Accession Gene name Description Regular XL Regular XL Regular XL Avg
Q8IUH3 RBM45 RNA-binding protein 45 969 þ þ þ þ þ þ þ þ 1 1 1
P14866 HNRNPL Heterogeneous nuclear ribonucleoprotein L 207 þ þ þ þ þ þ þ þ þ þ 1 1 1
P22626 HNRNPA2B1 Heterogeneous nuclear ribonucleoproteins A2/B1 113 þ þ þ þ þ þ þ þ þ þ 1 1 1 x
P43243 MATR3 Matrin-3 111 þ þ þ þ þ þ þ þ þ þ 1 1 1
Q00839 HNRNPU Heterogeneous nuclear ribonucleoprotein U 107 þ þ þ þ þ þ þ þ þ þ 1 1 1
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K 105 þ þ þ þ þ þ þ þ þ þ 1 1 1
P09651 HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 99 þ þ þ þ þ þ þ þ þ þ 1 1 1 x
Q93008 USP9X Probable ubiquitin carboxyl-terminal hydrolase FAF-X 97 þ þ þ þ þ 1 1
Q9NZI8 IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 63 þ þ 1 1
Q8N163 CCAR2 Cell cycle and apoptosis regulator protein 2 62 þ þ þ þ þ þ þ þ þ 1 1 1
P52272 HNRNPM Heterogeneous nuclear ribonucleoprotein M 60 þ þ þ þ þ 1 1
Q08211 DHX9 ATP-dependent RNA helicase A 60 þ þ þ þ þ þ þ þ þ 1 1 1
P08107 HSPA1A Heat shock 70 kDa protein 1A/1B 58 þ þ 1 1
Q13263 TRIM28 Transcription intermediary factor 1-beta 55 þ þ þ þ þ 1 1
P11940 PABPC1 Polyadenylate-binding protein 1 52 þ þ 1 1 x x
P51991 HNRNPA3 Heterogeneous nuclear ribonucleoprotein A3 50 þ þ þ þ þ þ þ þ þ 1 1 1
P07910 HNRNPC Heterogeneous nuclear ribonucleoproteins C1/C2 48 þ þ þ þ þ þ þ þ þ 1 1 1
P38159 RBMX RNA-binding motif protein, X chromosome 41 þ þ þ þ þ þ þ þ 1 1 1
O43390 HNRNPR Heterogeneous nuclear ribonucleoprotein R 32 þ þ þ þ þ þ þ þ 1 1 1
Q13148 TARDBP TAR DNA-binding protein 43 27 þ þ þ þ 1 1
Q15717 ELAVL1 ELAV-like protein 1 26 þ þ þ þ þ þ þ þ 1 1 1
Q92841 DDX17 Probable ATP-dependent RNA helicase DDX17 25 þ þ þ þ þ þ þ 1 1
Q96PK6 RBM14 RNA-binding protein 14 25 þ þ þ þ þ þ þ þ 1 1 1
P23246 SFPQ Splicing factor, proline- and glutamine-rich 23 þ þ þ þ 1 1
Q13310 PABPC4 Polyadenylate-binding protein 4 23 þ þ þ þ 1 1
Q14103 HNRNPD Heterogeneous nuclear ribonucleoprotein D0 23 þ þ þ þ þ þ þ þ 1 1 1
Q9NZB2 FAM120A Constitutive coactivator of PPAR-gamma-like protein 1 21 þ þ þ þ 1 1
P09874 PARP1 Poly [ADP-ribose] polymerase 1 20 þ þ þ þ 1 1
P68104 EEF1A1 Elongation factor 1-alpha 1 20 þ þ þ þ 1 1
P78347 GTF2I General transcription factor II-I 20 þ þ þ þ 1 1
Q96PU8 QKI Protein quaking 20 þ þ þ þ 1 1
O75643 SNRNP200 U5 small nuclear ribonucleoprotein 200 kDa helicase 19 þ þ þ þ 1 1
Q15366 PCBP2 Poly(rC)-binding protein 2 19 þ þ þ þ þ þ þ þ 1 1 1
Q92945 KHSRP Far upstream element-binding protein 2 19 þ þ þ þ 1 1
Q99729 HNRNPAB Heterogeneous nuclear ribonucleoprotein A/B 19 þ þ þ þ þ þ þ þ 1 1 1
O15042 U2SURP U2 snRNP-associated SURP motif-containing protein 18 þ þ þ þ 1 1
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 18 þ þ þ þ 1 1
P13639 EEF2 Elongation factor 2 16 þ þ þ þ 1 1
P60709 ACTB Actin, cytoplasmic 1 16 þ þ þ þ 1 1
P62269 HIST1H4A Histone H4 15 þ þ þ þ 1 1
O00425 IGF2BP3 Insulin-like growth factor 2 mRNA-binding protein 3 14 þ þ þ þ 1 1
O43143 DHX15 Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 14 þ þ þ þ 1 1
Q9Y2L1 DIS3 Exosome complex exonuclease RRP44 14 þ þ þ þ 1 1
P01614 [Ig kappa chain V-II region Cum] 13 þ þ þ þ 1 1
P07437 TUBB Tubulin beta chain 12 þ þ þ þ 1 1
P35637 FUS RNA-binding protein FUS 12 þ þ þ þ 1 1
Q7L2E3 DHX30 Putative ATP-dependent RNA helicase DHX30 12 þ þ þ þ 1 1
Q6PKG0 LARP1 La-related protein 1 11 þ þ þ þ 1 1
Q9Y6M1 IGF2BP2 Insulin-like growth factor 2 mRNA-binding protein 2 11 þ þ þ þ 1 1
P62988 UBB Ubiquitin 10 þ þ þ þ 1 1
Q9UKM9 RALY RNA-binding protein Raly 10 þ þ þ þ 1 1
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P25205 MCM3 DNA replication licensing factor MCM3 8 þ þ þ þ 1 1
Q99623 PHB2 Prohibitin-2 8 þ þ þ þ 1 1
O75688 PPM1B Protein phosphatase 1B 64 þ þ þ þ þ 0.97 0.97
P62805 HSPD1 60 kDa heat shock protein, mitochondrial 15 þ þ 0.88 0.88
P26599 PTBP1 Polypyrimidine tract-binding protein 1 20 þ þ þ þ þ þ þ þ 0.67 1 0.835
Q13151 HNRNPA0 Heterogeneous nuclear ribonucleoprotein A0 20 þ þ þ þ þ þ þ þ 1 0.67 0.835
P31943 HNRNPH1 Heterogeneous nuclear ribonucleoprotein H 16 þ þ þ þ þ þ þ þ 1 0.67 0.835
P10809 RPS18 40S ribosomal protein S18 15 þ þ þ þ þ þ þ þ 1 0.67 0.835 x x x
Q14974 KPNB1 Importin subunit beta-1 14 þ þ þ þ þ þ þ þ 1 0.67 0.835 x
P63241 EIF5A Eukaryotic translation initiation factor 5A-1 11 þ þ þ þ 0.67 0.67
P12956 XRCC6 X-ray repair cross-complementing protein 6 9 þ þ þ þ 0.67 0.67 x
Q86U42 PABPN1 Polyadenylate-binding protein 2 9 þ þ þ þ 0.67 0.67
O60814 HIST1H2BK Histone H2B type 1-K 7 þ þ þ þ 0.67 0.67
P62701 RPS4X 40S ribosomal protein S4, X isoform 7 þ þ þ þ 0.67 0.67 x x x
P04908 HIST1H2AB Histone H2A type 1-B/E 6 þ þ þ þ 0.67 0.67
P55060 CSE1L Exportin-2 6 þ þ þ þ 0.67 0.67 x
P62316 SNRPD2 Small nuclear ribonucleoprotein Sm D2 6 þ þ þ þ 0.67 0.67
P84090 ERH Enhancer of rudimentary homolog 6 þ þ þ þ 0.67 0.67
P05388 RPLP0 60S acidic ribosomal protein P0 5 þ þ þ þ 0.67 0.67 x
P08238 HSP90AB1 Heat shock protein HSP 90-beta 5 þ þ þ þ 0.67 0.67
P19338 NCL Nucleolin 5 þ þ þ þ 0.67 0.67
P49327 FASN Fatty acid synthase 5 þ þ þ þ 0.67 0.67
P52597 HNRNPF Heterogeneous nuclear ribonucleoprotein F 5 þ þ þ þ 0.67 0.67
P62314 SNRPD1 Small nuclear ribonucleoprotein Sm D1 5 þ þ þ þ 0.67 0.67
P62318 SNRPD3 Small nuclear ribonucleoprotein Sm D3 5 þ þ þ þ 0.67 0.67
Q15029 EFTUD2 116 kDa U5 small nuclear ribonucleoprotein component 5 þ þ þ þ 0.67 0.67
Q8IY67 RAVER1 Ribonucleoprotein PTB-binding 1 5 þ þ þ þ 0.67 0.67
Q9Y2W1 THRAP3 Thyroid hormone receptor-associated protein 3 5 þ þ þ þ 0.67 0.67
P15927 RPA2 Replication protein A 32 kDa subunit 4 þ þ þ þ 0.67 0.67
Q12906 ILF3 Interleukin enhancer-binding factor 3 23 þ þ þ þ þ þ þ þ 0.33 1 0.665
O60506 SYNCRIP Heterogeneous nuclear ribonucleoprotein Q 21 þ þ þ þ þ þ þ þ 1 0.33 0.665
P68363 TUBA1B Tubulin alpha-1B chain 15 þ þ þ þ þ þ þ þ 1 0.33 0.665
P52294 KPNA1 Importin subunit alpha-5 13 þ þ þ þ þ þ þ þ 1 0.33 0.665 x
Q12905 ILF2 Interleukin enhancer-binding factor 2 11 þ þ þ þ þ þ þ þ 0.66 0.67 0.665
P68032 ACTC1 Actin, alpha cardiac muscle 1 7 þ þ 0.66 0.66
P01859 IGHG2 [Ig gamma-2 chain C region] 10 þ þ þ þ þ þ 0.97 0.33 0.65
P39019 RPS19 40S ribosomal protein S19 6 þ þ 0.65 0.65 x x x
O14979 HNRNPDL Heterogeneous nuclear ribonucleoprotein D-like 14 þ þ þ þ þ þ þ þ 0.67 0.33 0.5
P67809 YBX1 Nuclease-sensitive element-binding protein 1 12 þ þ þ þ þ þ þ þ 1 0 0.5
P05141 SLC25A5 ADP/ATP translocase 2 9 þ þ þ þ þ þ þ þ 0 1 0.5
P08779 KRT16 [Keratin, type I cytoskeletal 16] 13 þ þ 0.33 0.33
P23396 RPS3 40S ribosomal protein S3 7 þ þ þ þ þ þ þ þ 0.66 0 0.33 x x x
Q15233 NONO Non-POU domain-containing octamer-binding protein 4 þ þ þ þ 0.33 0.33
Q15365 PCBP1 Poly(rC)-binding protein 1 4 þ þ þ þ 0.33 0.33
Q99459 CDC5L Cell division cycle 5-like protein 4 þ þ þ þ 0.33 0.33
Q99873 PRMT1 Protein arginine N-methyltransferase 1 4 þ þ þ þ 0.33 0.33
Q9BXP5 SRRT Serrate RNA effector molecule homolog 4 þ þ þ þ 0.33 0.33
P09429 HMGB1 High mobility group protein B1 3 þ þ þ þ 0.33 0.33
P42704 LRPPRC Leucine-rich PPR motif-containing protein, mitochondrial 3 þ þ þ þ 0.33 0.33
P43246 MSH2 DNA mismatch repair protein Msh2 3 þ þ þ þ 0.33 0.33
P62851 RPS25 40S ribosomal protein S25 3 þ þ þ þ 0.33 0.33 x x x
Q04837 SSBP1 Single-stranded DNA-binding protein, mitochondrial 3 þ þ þ þ 0.33 0.33
Q13838 DDX39B Spliceosome RNA helicase DDX39B 3 þ þ þ þ 0.33 0.33
Q9BUJ2 HNRNPUL1 Heterogeneous nuclear ribonucleoprotein U-like protein 1 3 þ þ þ þ 0.33 0.33
Q9UPT8 ZC3H4 Zinc ﬁnger CCCH domain-containing protein 4 3 þ þ þ þ 0.33 0.33
P46782 RPS5 40S ribosomal protein S5 5 þ þ 0.32 0.32 x x x
P62913 RPL11 60S ribosomal protein L11 9 þ þ þ þ þ þ 0.59 0 0.295 x
P06748 NPM1 Nucleophosmin 5 þ þ þ þ þ þ 0 0 0
P26373 RPL13 60S ribosomal protein L13 4 þ þ 0 0 x
P05387 RPLP2 60S acidic ribosomal protein P2 3 þ þ 0 0 x
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Table 1 (continued )
Proteins Spectral count sum Fold spectra increase AvgP Canonical pathway
Manual SAINTexpress SAINTexpress EIF2 eIF4/p70S6K mTOR Telomere Ext. RAN
Accession Gene name Description Regular XL Regular XL Regular XL Avg
P14174 MIF Macrophage migration inhibitory factor 3 þ þ þ þ 0 0
P46783 RPS10 40S ribosomal protein S10 3 þ þ þ þ 0 0 x x x
P62263 RPS14 40S ribosomal protein S14 3 þ þ þ þ 0 0 x x x
P62917 RPL8 60S ribosomal protein L8 3 þ þ þ þ 0 0 x
P82673 MRPS35 28S ribosomal protein S35, mitochondrial 3 þ þ þ þ 0 0
P84103 SRSF3 Serine/arginine-rich splicing factor 3 3 þ þ þ þ 0 0
Q13283 G3BP1 Ras GTPase-activating protein-binding protein 1 3 þ þ þ þ 0 0
Q16576 RBBP7 Histone-binding protein RBBP7 3 þ þ þ þ 0 0
Q7Z5L9 IRF2BP2 Interferon regulatory factor 2-binding protein 2 3 þ þ þ þ 0 0
Q9HAV4 XPO5 Exportin-5 3 þ þ þ þ 0 0
P05386 RPLP1 60S acidic ribosomal protein P1 2 þ þ þ þ 0 0 x
P06313 [Ig kappa chain V–IV region JI] 2 þ þ þ þ 0 0
P31942 HNRNPH3 Heterogeneous nuclear ribonucleoprotein H3 2 þ þ þ þ 0 0
P38919 EIF4A3 Eukaryotic initiation factor 4A-III 2 þ þ þ þ 0 0 x x x
P60842 EIF4A1 Eukaryotic initiation factor 4A-I 2 þ þ þ þ 0 0 x x x
P60866 RPS20 40S ribosomal protein S20 2 þ þ þ þ 0 0 x x x
P62081 RPS7 40S ribosomal protein S7 2 þ þ þ þ 0 0 x x x
P62249 RPS16 40S ribosomal protein S16 2 þ þ þ þ 0 0 x x x
P62277 RPS13 40S ribosomal protein S13 2 þ þ þ þ 0 0 x x x
Q14498 RBM39 RNA-binding protein 39 2 þ þ þ þ 0 0
Q1KMD3 HNRNPUL2 Heterogeneous nuclear ribonucleoprotein U-like protein 2 2 þ þ þ þ 0 0
Q93009 USP7 Ubiquitin carboxyl-terminal hydrolase 7 2 þ þ þ þ 0 0
Q9BQ04 RBM4B RNA-binding protein 4B 2 þ þ þ þ 0 0
Q9H074 PAIP1 Polyadenylate-binding protein-interacting protein 1 2 þ þ þ þ 0 0 x x
P35908 bKRT2 [Keratin, type II cytoskeletal 2 epidermal] 41 þ þ þ þ þ þ
O15523 bDDX3Y Cluster of ATP-dependent RNA helicase DDX3Y 4 þ þ þ
P13647 bKRT5 [Keratin, type II cytoskeletal 5] 2 þ þ þ
[Description]¼putative contaminant.
Bold¼Externally Validated.
"þ"¼ fold change 2.5–100.
"þ þ"¼ fold change 101–1000.
"þ þ þ"¼ fold change 41000.
a Proteins listed were detected in either regular IP or crosslinking IP. The proteins were detected by either manual analysis or SAINTexpress algorithm. Candidate RBM45 protein interactors are identiﬁed using thresholding
analysis and probabilistic scoring of associations (SAINTexpress). Proteins are sorted by decreasing AvgP, higher values predict high likelihood of interaction. Fold-changes are computed from positive puriﬁcations against negative
control puriﬁcations (empty vector) are categorized as follows:þ 2.5–100, þþ 101–1000, þþþ 41000. Fold-change values are provided in the Supplemental Material section. Associations with top ﬁve canonical pathways are
highlighted (EIF2 Signaling (EIF2), Regulation of eIF4 and p7056K Signaling (eIF4/p7056K), mTOR Signaling (mTOR), Telomere Extension by Telomerase (Telomere Ext.), and RAN Signaling (RAN)). Starred proteins were only
identiﬁed in the thresholding analysis. Bracketed proteins were identiﬁed as putative contaminants in the CRAPome database (v1.1). Bolded proteins highlight interactions veriﬁed by immunoblot in the current or in the previous
study (Li et al., 2015).
b Gene¼manual analysis only (all others were found in both methods).
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Fig. 2. Veriﬁcation of RBM45 interacting proteins. (A) Pull-down of selected proteins with FLAG-RBM45 expressed in HEK293 cells. Crosslinking immunoprecipitations with
FLAG antibody or IgG were performed. The IP fractions were immunoblotted with hnRNP-L, hnRNP-A1, hnRNP-A2B1, Matrin-3, hnRNP-A3 and RBM14 antibodies. The same
IP fractions were also immunobloted with FLAG (FLAG-RBM45) and GAPDH (negative IP control) antibodies. (B) Immunoprecipitations of endogenous candidate proteins in
FLAG-RBM45 expressing cells shows that FLAG-RBM45 co-puriﬁed with the tested endogenous proteins. The endogenous candidate proteins were immunoprecipitated with
hnRNP-L, hnRNP-A1, Matrin-3 or RBM14 antibody, while IgG pull-down was used for IP control. The immunoblots were detected with FLAG antibody (FLAG-RBM45), tested
endogenous protein speciﬁc antibodies, and GAPDH antibody (negative IP control). Similar validation studies for TDP-43 and FUS were previously reported (Li et al., 2015).
(C) In-cell RNase treatment and crosslinking-IP were performed on cells expressing FLAG-RBM45. The amount of hnRNP-L, hnRNP-A1, the lower-molecular-weight band of
hnRNP-A2B1, Matrin-3 and RBM14 that co-puriﬁed with FLAG-RBM45 was reduced upon the RNase treatment. (D) The RBM45-(Δ286-318) construct, i.e. the homo-oli-
gomerization assembly (HOA) domain deﬁcient construct (Li et al., 2015), exhibits signiﬁcantly reduced binding to the tested candidate proteins when compared to full-
length-RBM45. Full-length FLAG-RBM45 or FLAG-Δ(286-318) construct were expressed in HEK293 cells. FLAG-IP was performed as described previously. Immunoblot
analysis shows that all the tested candidate proteins displayed reduced co-IP% with FLAG-Δ(286-318) as compared with the full-length FLAG-RBM45.
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IP (Supplemental Table 5), and 36 were found in both regular-IP
and crosslinking-IP groups (Supplemental Table 6). Analysis of the
average number of total spectrum counts by different im-
munoprecipitation groups showed that in both regular IP and
crosslinking IP, the proteins identiﬁed from empty vector groups
were signiﬁcantly lower than the proteins identiﬁed from FLAG-/
HA-IP groups, providing further evidence of the speciﬁcity of the
approach (Supplemental Fig. 2).
2.2. Validation of select RBM45 PPIs
We have previously demonstrated that FLAG-RBM45 associates
with ALS-linked proteins TDP-43 and FUS in HEK293 cells by im-
munoblot (Li et al., 2015). As expected, both TDP-43 and FUS were
detected in the current IP–MS study (Table 1 and Supplemental
Table 1). We next conﬁrmed speciﬁc interactions of severalidentiﬁed candidate proteins with RBM45 by co-im-
munoprecipitation (co-IP) followed by immunoblot (Fig. 2A):
hnRNP-L, hnRNP-A1, hnRNP-A2B1, Matrin-3, hnRNP-A3, and
RBM14. All of these candidate proteins were in the top 20% highest
interaction probability and abundance (spectral counts), and
identiﬁed in both the regular and crosslinking IP experiments
(Table 1). We stably expressed FLAG-RBM45 in HEK293 cells and
performed co-IP from whole cell lysates. To detect transient or
weak interactions, the cells were treated with formaldehyde to
cross-link associated proteins prior to co-IP analysis. Anti-FLAG co-
IP experiments demonstrated that all the proteins tested co-pur-
iﬁed with FLAG-RBM45 but not with IgG (Fig. 2A). GAPDH, which
was not identiﬁed by mass spectrometry, was used as negative
control to further demonstrate the speciﬁcity of the observed in-
teractions. As expected, we failed to detect association of GAPDH
and FLAG-RBM45 (Fig. 2A, bottom). Moreover, we performed re-
ciprocal co-IP assays using whole cell lysate from HEK293 cells
Y. Li et al. / Brain Research 1647 (2016) 79–9386expressing FLAG-RBM45 and antibodies against the selected can-
didate proteins. The reciprocal co-IP analysis demonstrated that
FLAG-RBM45 co-puriﬁed with endogenous hnRNP-L, hnRNP-A1,
Matrin-3 and RBM14 proteins (Fig. 2B). Taken together, these data
provide evidence of the validity of the IP–MS approach and con-
ﬁrm speciﬁc interactions of selected candidate proteins with
RBM45.
Since RBM45 contains three RRM domains, it may associate
with its interacting proteins through RNA–protein interactions. To
determine if associations between RBM45 and the previously
tested proteins are RNA-dependent, we used in-cell RNase treat-
ment prior to the cross-linking and anti-FLAG IP (Li et al., 2015).
The in-cell RNase treatment signiﬁcantly reduced the amounts of
the hnRNP-L, hnRNP-A1, Matrin-3 and RBM14 proteins that co-
puriﬁed with FLAG-RBM45 (Fig. 2C). Interestingly, the amount of
the lower-molecular-weight species (arrows, Fig. 2C) of the
hnRNP-A2B1 protein that was co-puriﬁed with FLAG-RBM45 re-
duced upon RNase treatment. However, the co-puriﬁed amount of
the higher-molecular-weight species of hnRNP-A2B1 was not af-
fected by RNase treatment (Fig. 2C). This result suggests that many
RBM45 PPIs are RNA-dependent.
2.3. RBM45 homo-oligomerization mediates association with a large
number of proteins
We previously reported that the RBM45 homo-oligomer as-
sembly (HOA) domain mediates association with TDP-43 and FUS
(Li et al., 2015). We hypothesize that the HOA domain serves as a
general protein–protein interaction mediator. To test this hypoth-
esis, we expressed FLAG-tagged constructs of either the full-length
RBM45 or the Δ(286-318) construct with the majority of the HOA
domain deleted and incapable of homo-oligomerization (Li et al.,
2015). Anti-FLAG co-IP analysis showed that the tested candidate
proteins co-puriﬁed efﬁciently with the FLAG-full-length RBM45.
However, the FLAG-Δ(286-318) construct exhibited signiﬁcantlyFig. 3. Enriched GO Biological Process terms. RBM45-interacting proteins were tested fo
Benjamini–Hochberg post-hoc p value correction. Terms with a p value of 0.001 or less w
proportion of shared proteins between terms was evaluated using the kappa statistic a
graph, with edge width proportional to kappa score. Leading terms, those terms with t
references to color in this ﬁgure legend, the reader is referred to the web version of threduced binding to all the tested candidate proteins (Fig. 2D).
These results suggest that the HOA domain is an important med-
iator of RBM45 PPIs and that homo-oligomerization of RBM45 is
required for many RBM45 PPIs.
2.4. Gene ontology and pathway analysis
To identify putative biological processes associated with
RBM45-interacting proteins, we performed enrichment analysis in
the Gene Ontology (GO) domain “Biological Process” (Fig. 3). The
results of this analysis identiﬁed two predominant themes:
(1) nuclear RNA processing and (2) cytoplasmic RNA translation.
RNA processing terms were chieﬂy related to splicing (e.g., “reg-
ulation of RNA splicing”, “alternative mRNA splicing”). Other nu-
clear RNA-associated terms included “mRNA transport”, “regulation
of mRNA stability”, and “nuclear export”. Cytoplasmic translational
themes were more diverse and included events directly to mRNA
translation (“translation initiation”, “translation termination”), as
well as downstream processing events (“protein targeting to ER”,
“nonsense mediated mRNA decay”). Finally, terms unrelated to
these phenomena and unconnected to any nodes included
“apoptotic nuclear changes” and “telomere maintenance” (Fig. 3).
To provide further insights into the biological processes iden-
tiﬁed by this approach, we took leading terms, those terms with
the highest number of associated proteins, from our results and
visualized these terms with their associated proteins in a network
layout where edges connect proteins to an associated biological
process (Fig. 4). The results show the individual proteins that re-
sult in the identiﬁcation of an enriched biological process. For
example, the identiﬁcation of the “mRNA metabolic process” and
“regulation of RNA splicing” terms results in large part from the
many hnRNP proteins in our list of RBM45-interacting proteins.
Conversely, the enrichment for “regulation of translation” results
from the presence of initiation and elongation factors (e.g., eIF
proteins) in our list of RBM45-interacting proteins (Fig. 4).r GO Biological Process enrichment using the right-sided hypergeometric test with
ere visualized in a network layout, where node size corresponds to term p value. The
nd nodes with a kappa score (κ) of at least 0.4 were connected with edges on the
he highest number of proteins, are colored for emphasis. (For interpretation of the
is article) .
Fig. 4. Leading terms with associated proteins. Leading terms from Fig. 3 were placed into a separate network and all associated proteins from the list of RBM45-interacting
proteins were visualized as nodes and connected to the appropriate term. Where a protein is associated with multiple terms, multiple edges emanate from that protein and
edges are color-matched to their associated terms. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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proteins were identiﬁed using Ingenuity Pathway Analysis (IPAs,
QIAGEN Redwood City). Out of a total of 103 pathways, 28 were
signiﬁcantly enriched (p-value lower than 0.05). The top 5 path-
ways, ranked by signiﬁcance and percent overlap are “EIF2 Sig-
naling”, “Regulation of eIF4 and p70S6K Signaling”, “mTOR Signal-
ing”, “Telomere Extension by Telomerase”, and “RAN Signaling”
(Table 1 and Supplemental Table 7). These results were consistent
with associations found in the gene ontology analysis. Collectively,
this view emphasizes the diverse array of biological functions
served by RBM45-interacting proteins.
2.5. Co-localization analysis
To assess the association of RBM45 and selected interacting
proteins in cells, we used immunocytochemistry of our FLAG-
RBM45 stable HEK293 cells together with digital deconvolution
and co-localization analysis. The results of this analysis are shown
in Fig. 5 and Supplemental Fig. 3. Because the staining we observe
for the majority of the proteins analyzed is predominantly nuclear
(Supplemental Fig. 3), multiple methods were used to provide a
quantitative measure of the extent of co-localization. We thus
analyzed the co-localization of FLAG-RBM45 and selected proteins
using Manders coefﬁcients (Bolte and Cordelieres, 2006) and the
intensity correlation quotient (ICQ) (Li et al., 2004), together with
pixel intensity scatter plots. The ICQ evaluates the co-variation of
pixel intensities for each protein and provides a correlation-based
metric (the ICQ, range 0.5 to 0.5) that reﬂects the degree to
which protein staining intensities vary in synchrony and asso-
ciated statistical signiﬁcance. If staining intensities vary in syn-
chrony (co-localization), the ICQ is large, positive, and statisticallysigniﬁcant. For proteins with subcellular segregation, the ICQ is
large, negative, and statistically signiﬁcant, while for random
variations in intensity, the ICQ¼0, p40.05.
The results of this analysis are shown in Fig. 5B. We used SMN
as a negative control, as the staining for this protein is pre-
dominantly cytoplasmic. As shown in Fig. 5B, by either measure of
co-localization, the association between RBM45 and SMN is low,
reﬂecting subcellular segregation, as anticipated. We then eval-
uated the extent of co-localization between RBM45 and several
RBM45-interacting proteins. FLAG-RBM45 staining was exclusively
nuclear and we evaluated the co-localization of RBM45 with sev-
eral nuclear hnRNP proteins. By both methods, the highest degree
of co-localization was observed between RBM45 and hnRNP-A1
(Fig. 5H). RBM45 also exhibited statistically signiﬁcant co-locali-
zation with hnRNP-A3, hnRNP-L, and Matrin-3, in descending or-
der of extent of co-localization (Fig. 5B). By contrast, RBM45 co-
localization with hnRNP-A2/B1 by either approach was lesser and
did not reach statistical signiﬁcance, despite a nuclear localization
for both proteins (Fig. 5A). This ﬁnding highlights the utility of
digital deconvolution and quantitative co-localization measures
for assessing the true extent of association between proteins by
immunocytochemistry. We also observed a lack of co-localization
between RBM45 and G3BP, the latter of which was predominantly
cytoplasmic. The absence of statistically signiﬁcant co-localization
between RBM45 and hnRNP-A2/B1 and G3BP may reﬂect the ab-
sence of required stimuli/signaling events necessary for the in-
teraction of these proteins. The association of RBM45 and G3BP, for
example, most likely occurs in cytoplasmic stress granules that not
observed under basal conditions (Li et al., 2015).
Fig. 5. Co-localization analysis. (A–G) The co-localization of RBM45 and the indicated proteins were evaluated using immunocytochemistry together with image decon-
volution and co-localization analysis. Representative images and pixel intensity scatter plots are shownwith cutouts at higher magniﬁcation to highlight detail. (H) Statistical
analysis of protein co-localization. M1¼RBM45 overlap with indicated protein. M2¼ indicated protein overlap with RBM45. ICQ¼ intensity correlation quotient. p ICQ¼p
value of ICQ. Manders coefﬁcients (M1 and M2) measure the proportion of co-localizing proteins in each channel of a two-channel image and are shown as mean7SEM. The
intensity correlation quotient (ICQ) has a range of 0.5 (perfect segregation) to 0.5 (perfect co-localization), with random intensity variation resulting in a value 0. The
statistical signiﬁcance of each ICQ value is shown at far right. SMN staining was used as a negative control.
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We used IP–MS to identify RBM45 PPIs and gain insight into the
biological functions of this ALS/FTLD-associated RNA-binding
protein (RBP) in HEK293 cells. By employing two complementary
IP methods, regular IP and formaldehyde crosslinking-IP, we de-
tected 132 RBM45 PPIs with high conﬁdence. Our ability to iden-
tify numerous RBM45 PPIs with high conﬁdence was a result of
our stringent IP–MS approach. We identiﬁed 132 “true” interactors
along with another 6 proteins matched to putative contaminants
in the CRAPome database (Mellacheruvu et al., 2013). Triplicate IPs
were analyzed by mass spectrometry. Identiﬁed proteins were
subjected to a manual thresholding approach (resulting in 132
hits) and a probabilistic approach (resulting in 131 hits) to remove
non-speciﬁcally bound proteins and predict putative PPIs. The
resulting candidate proteins overlapped at 98.9%, highlighting the
robustness of analytical method. RBPs were the most prominent
protein family identiﬁed by our analytical approach, both in
overall number of proteins and individual protein spectral counts.
Taking the list of RBM45 PPIs, we next used enrichment andpathway analysis to link RBM45 PPIs to putative biological func-
tions and pathways. The results showed enrichment for nuclear
RNA processing via hnRNPs and cytoplasmic translation functions
via eiF2 and eiF4 pathways. Taken together, these results provide
new insights into the PPIs, biological functions, and roles in ALS/
FTLD of RBM45.
These insights are necessary to further understand the role of
RBM45 (and RBPs more generally) in ALS/FTLD. RBM45 is a com-
ponent of ubiquitinated inclusions in neurons and glial cells in
ALS, FTLD, and AD patients (Collins et al., 2012). The mechanisms
mediating the protein's incorporation into inclusions are poorly
understood, however. RBM45 is distinct from other inclusion
forming RBPs, such as TDP-43, FUS, TAF15, and hnRNP-A1, in that
it does not possess a prion-like domain (King et al., 2012). RBM45
does, however, contain a homo-oligomerization (HOA) domain
that mediates RBM45 self-association and association with other
RBPs, including TDP-43 and FUS, suggesting a role for this domain
in RBM45 inclusion formation (Li et al., 2015). Consistent with this
notion, we identify numerous inclusion-forming RBPs that bind to
RBM45 via our IP–MS approach, including hnRNP-A1, hnRNP-A2/
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these proteins, the HOA domain is requisite for interaction
(Fig. 2D). Thus, while the HOA domain is likely necessary for
normal RBM45 functions, its role in mediating RBM45 oligomer-
ization and association with other RBPs suggests this domain also
contributes to the pathological aggregation of RBM45 and other
RBPs in ALS/FTLD. The presence of prion-like domains in many
RBM45 interacting proteins and the lack of a prion domain in
RBM45 also suggests that RBM45 aggregation may be driven by its
association with other aggregation-prone RBPs, as has been ob-
served for RBPs such as PSF and NONO found in TDP-43/FUS po-
sitive aggregates (Dammer et al., 2012; Shelkovnikova et al., 2014).
Matrin-3 is a nuclear matrix protein implicated in binding and
stabilizing mRNA and Matrin-3 mutations have been linked to ALS
(Johnson et al., 2014). While Matrin-3 has not been associated
with cytoplasmic inclusions in ALS, interactions between RBM45
and Matrin-3 within the nucleus may contribute to the regulation
of mRNA stability and transport within the nucleus. The identiﬁ-
cation of numerous ALS-associated proteins within our RBM45 PPI
list suggests that RBM45 can directly contribute to disease by
virtue of its association with these proteins.
The aggregation of RBPs in ALS/FTLD confers toxicity both by
aggregation-induced toxic gain of function as well as aggregation-
induced loss of normal RBP function. Thus, understanding the
normal functions of RBPs is critical to identifying molecular me-
chanisms of disease and potential therapeutic targets. RBPs are
typically multifunctional and act in both the nucleus and cyto-
plasm, inﬂuencing transcription, RNA splicing, RNA export, trans-
lation, and transport of mRNAs (Dreyfuss et al., 2002). Interest-
ingly, RBM45 associates with many of the validated binding pro-
teins via RNA-mediated interactions (Fig. 2), suggesting that
RBM45 and its binding proteins share the regulation of speciﬁc
RNA targets. We used our list of RBM45-interacting proteins to
generate a list of putative RBM45 biological functions and asso-
ciated pathways using Gene Ontology and pathway analysis. Two
major themes emerged: nuclear RNA processing/splicing via
hnRNPs and cytoplasmic translation via the eiF2 and eiF4 path-
ways (Figs. 3 and 4; Supplemental Table 7). The many splicing-
associated proteins in our list (Fig. 4) suggest a role for RBM45 in
the regulation of splicing events. Dysregulation of RNA splicing is a
well-characterized phenomenon in ALS/FTLD and can result from
RBP cytoplasmic mis-localization, aggregation, or both (Walsh
et al., 2015). Loss of individual RBP function due to these phe-
nomena can have profound effects on transcriptional regulation.
For example, TDP-43 and FUS bind to more than 50% of the human
transcriptome and the loss of these proteins results in substantial
global alterations in transcription and splicing (Lagier-Tourenne
et al., 2012; Polymenidou et al., 2011; Tollervey et al., 2011). We
anticipate that future studies directly examining the role of RBM45
in the regulation of transcription and RNA splicing will likewise
reveal widespread RBM45 binding across the transcriptome and
substantial inﬂuence on mRNA splicing decisions.
In further support of this notion, the identiﬁcation of RBM45
PPIs with 19 members of the hnRNP family suggests considerable
functional overlap between RBM45 and this diverse class of pro-
teins. Spectral count values for many of these proteins were
among the highest observed in our study (Table 1) and we ac-
cordingly predict considerable functional overlap between RBM45
and the hnRNP family. hnRNPs participate in a variety of mRNA
processing/maturation processes, including mRNA maturation,
splicing, nuclear export, and 3′-end processing (Kim and Dreyfuss,
2001). Abnormalities in the expression/function of hnRNPs are
associated with a number of human diseases, including ALS by
virtue of the recent demonstration that mutations in the prion
domains of hnRNP-A2/B1 and hnRNP-A1 cause familial forms of
ALS (Kim et al., 2013). Our analysis of the co-localization of RBM45and these proteins demonstrates that RBM45 co-localizes most
highly with hnRNP-A1, followed by hnRNP-A3 and hnRNP-L, with
low, non-signiﬁcant co-localization observed with hnRNP-A2/B1
(Fig. 5).
The association of RBM45 with hnRNP-A1, together with the
aggregation-prone prion-like domain of hnRNP-A1, may thus
mediate both the function and aggregation of RBM45. We observe
a high degree of nuclear co-localization between these proteins
(Fig. 5) and conﬁrmed their physical, RNA-dependent interaction
via co-immunoprecipitation (Fig. 2C). hnRNP-A1 serves many
purposes in the nucleus, including regulating the transcription of
numerous genes (Jean-Philippe et al., 2013). Transcriptional reg-
ulation by hnRNP-A1 is, in part, conferred by its ability to bind and
relax G-quadruplex nucleic acid structures, including the fALS-
linked c9ORF72 GGGGCC hexanucleotide repeat expansion
(Cooper-Knock et al., 2014; Fukuda et al., 2002). RBM45 may thus
be sequestered to c9ORF72 repeat expansion G-quadruplex
structures in c9-linked fALS cases, causing a loss of normal RBM45
functions. Indeed, we identify numerous c9ORF72 repeat expan-
sion binding proteins, including FUS, ELAVL1, hnRNP-K, hnRNP-L,
hnRNP-Q, and hnRNP-U, as RBM45 PPIs (Table 1) (Cooper-Knock
et al., 2014; Mori et al., 2013). Despite its high afﬁnity for poly(G)/
(C) RNA (Tamada et al., 2002), RBM45 binding to c9ORF72 has not
been shown, although discrepancies between experimental ap-
proaches and results suggest that additional c9-binding RBPs re-
main as yet unidentiﬁed (Cooper-Knock et al., 2014; Mori et al.,
2013).
We also found signiﬁcant co-localization of RBM45 with
hnRNP-L and hnRNP-A3 in the nucleus (Fig. 5). hnRNP-L is a
multifunctional protein that regulates transcript splicing (Hui
et al., 2003b), stability (Hui et al., 2003a), and translation (Ma-
jumder et al., 2009). The protein affects splice site decisions for a
large number of transcripts and is capable of inhibiting spliceo-
some assembly via coordinated action with hnRNP-A1 (Chiou
et al., 2013; Hung et al., 2008). These results, together with their
RNA-dependent physical interaction (Fig. 2C) and co-localization
of RBM45 with these proteins (Fig. 5), provides further evidence of
a role for RBM45 in mRNA splicing decisions. hnRNP-A3 is in-
volved in the nucleocytoplasmic trafﬁcking of mRNA (Ma et al.,
2002) and is involved in telomere maintenance and protection by
virtue of its direct binding to telomeres (Huang et al., 2010; Tanaka
et al., 2007). The protein is also a component of p62 positive/TDP-
43 negative inclusions in c9ORF72-linked fALS motor neurons
(Mori et al., 2013). hnRNP-A3 is a component mRNP complexes
that act to stabilize mRNA (Papadopoulou et al., 2012). The co-
localization of RBM45 and hnRNP-A3 within distinct nuclear foci
(Fig. 5, Supplemental Fig. 3) suggests a possible role for RBM45 in
this process as well.
A variety of cytoplasmic RBP functions also contribute to cel-
lular function and studies have repeatedly shown that loss of these
functions negatively impact cellular viability. TDP-43, for example,
associates with cytoplasmic stress granules (Colombrita et al.,
2009), regulates local mRNA translation (Wang et al., 2008), and
participates in RNA transport (Narayanan et al., 2013). Our results
likewise suggest important cytoplasmic functions for RBM45 in
both normal cellular homeostasis and disease. We identiﬁed RNA
transport as a biological process putatively regulated by RBM45
(Fig. 3). The interaction of RBM45 with ELAVL1, a known RNA
transport protein (Kraushar et al., 2014), is consistent with a role
for RBM45 in the transport of mRNA and local translation (Fig. 4).
We also identiﬁed enrichment in numerous biological processes
directly and indirectly related to cytoplasmic translation. A direct
role for RBM45 in translation is predicted from the identiﬁcation
of numerous elongation and initiation factors (e.g., eiF4a, eiF5A,
EEF2, … [Fig. 4]) as RBM45 interactors. Twelve percent of the eiF2
signaling pathway responsible for charged tRNA delivery to the
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RBM45, highlighting a possible role of RBM45 in early translational
events (Supplemental Table 7). Indirect contributions to transla-
tion included the GO Biological Process “Protein Targeting to ER”
(Fig. 3). ER stress occurs in ALS (Lautenschlaeger et al., 2012) and
RNA-binding proteins may directly associate with ER to modulate
its functions in certain cell/tissue types (Gautrey et al., 2005).
Despite these ﬁndings, immunocytochemical analysis shows an
exclusively nuclear staining pattern for RBM45 in HEK293 cells
(Supplemental Fig. 3). However we hypothesize that RBM45 can
mediate nuclear mRNA export via its association with nucleocy-
toplasmic shuttling hnRNP's, such as hnRNP-A1, hnRNP-L, and
hnRNP-K (Kim et al., 2000).
One limitation of the current approach is that our analyses
were performed exclusively in HEK293 cells. HEK293 cells have a
unique gene expression proﬁle, rapidly divide, and have an un-
stable karyotype. Each of these properties could inﬂuence the list
of RBM45 PPIs detected in the present work. Future studies are
necessary to determine cell-type and phenotype-speciﬁc RBM45
PPIs and how these contribute to cellular physiology. One area of
particular interest is the role of RBM45 in cell division and cell
type speciﬁcation. The initial characterization of RBM45 demon-
strated developmental regulation and neuronal enrichment of
RBM45 expression, suggesting that RBM45 and, by extension,
RBM45 PPIs contribute to cell division and organismal develop-
ment. Delineating which RBM45 PPIs occur in differentiated cell
populations, such as neurons, may likewise yield insight into
RBM45 PPIs and cellular functions that lead to its incorporation
into inclusions in ALS/FTLD. While stress is known to induce cy-
toplasmic stress granules to modulate translation, chronic stress
has been proposed to induce the generation of cytoplasmic in-
clusions from stress granules (Wolozin and Apicco, 2015). Further
studies examining the RBM45 protein complexes under stress
conditions may identify biological pathways relevant to the in-
duction of RBM45 aggregation and inclusion formation.
Finally, we used multiple immunoprecipitation methods cou-
pled with mass spectrometry to increase the conﬁdence of our
results. Two different tagged RBM45 constructs as well as the
presence or absence of a formaldehyde crosslinking method were
used for immunoprecipitation. We used a combination of cross-
linking and regular IP to distinguish weak and strong interactions,
respectively. While commonly used to identify PPIs, regular IP may
also yield non-physiological protein associations resulting from
artefactual, non-speciﬁc binding after cell lysis (Mili and Steitz,
2004). Formaldehyde is a mild, cell-permeable and reversible
crosslinker with very short spacer length (2.3–2.7 Å) and cross-
links only closely associated proteins (Klockenbusch and Kast,
2010). In vivo formaldehyde crosslinking-IP can help reduce in-
teraction artifacts introduced after cell lysis and help preserve
transient and/or weak protein–protein interactions and has been
used for discovering novel protein–protein interactions in many
proteomics studies (Corgiat et al., 2014; Klockenbusch and Kast,
2010; Miernyk and Thelen, 2008; Sutherland et al., 2008; Zhang
et al., 2009). Crosslinking-IP also facilitates stringent im-
munoprecipitations via increased detergent concentration, soni-
cation and extensive washes. Identiﬁcation of a protein only in
crosslinking-IP experiments suggests that the interaction with
RBM45 is weak. However, one cannot predict the biologic sig-
niﬁcance of the interaction with RBM45 based solely in whether
the interaction is strong or weak. Of the identiﬁed 132 proteins, 68
proteins were found solely in crosslinking-IP, while only 28 pro-
teins were found exclusively in regular IP. It is possible that the
protein-binding sites in these 28 proteins were masked by the
crosslinking reaction and thus not detected by crosslinking-IP.
Collectively, our results demonstrate that RBM45 associates
with a large and functionally diverse set of protein bindingpartners. Functions served by these proteins, particularly the
hnRNPs, suggest plausible and previously unknown biological
functions for RBM45. The identiﬁcation of these functions and the
association of RBM45 with numerous ALS-associated RBPs points
to RBM45-mediated mechanisms of disease in ALS/FTLD and
provides further insight into the pathological aggregation of
RBM45 occurring in neurodegenerative disease. The association of
RBM45 with the set of proteins identiﬁed herein provides new
directions for future studies of RBM45's role in neuronal devel-
opment, the regulation of gene expression, and
neurodegeneration.4. Experimental procedure
4.1. Cell culture and plasmid construction
HEK293 (FreeStyle™ 293-F Cells, Invitrogen) cells were cul-
tured in DMEM medium with 10% FBS and 1% Pen-Strep at 37°C
with 5% CO2. Transfection was performed using the Lipofectamine
2000 (Life technologies) and stable cell lines were selected in the
presence of 500 μg/ml G418 (Life Technologies) 48 h post-trans-
fection. The RBM45 cDNA clone plasmid, cGST-hRBM45
(HsCD00356971), was obtained from the DNASU Plasmid Re-
pository at Arizona State University, Tempe. The cDNA was am-
pliﬁed by PCR using Phusion High-Fidelity DNA Polymerase (NEB)
and sub-cloned into the pcDNA3 vector (Invitrogen). The 3xFLAG
tag (DYKDHDGDYKDHDIDYKDDDDK) or 2xHA tag (DY-
PYDVPDYAGGAAYPYDVPDYA) was appended to the N-terminus of
speciﬁc proteins to generate the 3xFLAG-or 2xHA-tagged
construct.
4.2. LC-MS/MS protein identiﬁcation
4.2.1. Immunoprecipitation
Each immunoprecipitation (IP) was carried out in triplicate.
Stable cell lines expressing FLAG-RBM45, HA-RBM45, or pcDNA3
vector were grown on 10 cm plates till 90% conﬂuent and har-
vested. For regular IP, cells from one 10 cm plate were lysed with
500 μl of 0.5% NP40 lysis buffer (50 mM HEPES pH 7.6, 150 mM
KCl, 2 mM EDTA, 0.5% NP40, 0.5 mM DTT and protease (Sigma
P8340)/phosphatase (Calbiochem 524629)/RNase inhibitors (Am-
bion AM2694)) at 4 °C for 15 min. For formaldehyde crosslinking-
IP, formaldehyde in-cell crosslinking was performed prior to IP as
previously reported (Li et al., 2015). Cells from one 10 cm plate
were suspended in 1 ml PBS containing 0.1% formaldehyde and
incubated at room temperature for 7 min with gentle agitation.
The suspension was spun for 3 min at 1800g at room temperature
and the supernatant was discarded. The pellet was washed with
1 ml 1.25 M glycine in cold PBS twice to quench the crosslinking
reaction. The pellet was further washed in PBS, lysed with 500 μl
of 1% NP40 lysis buffer (50 mM HEPES pH 7.6, 150 mM KCl, 2 mM
EDTA, 1% NP-40, 0.5 mM DTT and protease/phosphatase inhibitors)
at 4 °C and sonicated in a water bath sonicator (Misonix Sonicator
3000) at level 2 for 4 cycles (15 s on/30 s off).
The lysates were ﬁrst cleared by spinning at 16,000g at 4°C for
15 min to remove cell debris, pre-cleared using IgG–Agarose
(Sigma A0919) for 1 h and further centrifugated. 3 mg of total
protein was used for immunoprecipitation with 50 μg of either
pre-crosslinked antibody or IgG. FLAG-IP was performed using
anti-FLAG M2 Afﬁnity Gel (Sigma A2220), HA-IP was performed
using anti-HA Agarose (Sigma A2095), and IgG-IP control was
performed using Mouse IgG-Agarose (Sigma A0919). IPs were
performed at 4 °C for 2 h and the beads were washed six times in
IP buffer. The proteins were eluted with SDS sample buffer and
heated at 95 °C for 5 min for regular IP samples and heated for
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were then run on the Bolt 4–12% Bis-Tris Plus Gel (Life Technolo-
gies), and stained using Bio-Safe Coomassie Stain (BioRad).
4.2.2. Protein digestion
Gel lanes in the molecular weight range between 10 kDa and
greater than 250 kDa were excised into individual fractions, ex-
cluding the stained IgG-H (52 kDa) and IgG-L (25 kDa) bands.
Bands fractions were then further reduced into cubes of 1–2 mm3,
destained, washed, dried and further processed using an estab-
lished method (Shevchenko et al., 2006). Brieﬂy, each fraction was
reduced using 10 mM DTT (6 °C for 30 min) and alkylated using
55 mM iodoacetamide (room temperature for 30 min, in the dark),
using multiple hydration and dehydration cycles of the acrylamide
gel. Fractions were then digested using 20 ng/mL of Trypsin Gold
(Promega) (37 °C, overnight). Finally, peptides were extracted,
concentrated to dryness under vacuum and stored at 20 °C until
LC–MS analysis.
4.2.3. LC–MS analysis
Each fraction was reconstituted in 0.1% formic acid and ana-
lyzed using online liquid chromatography on a nanoAcquity-UPLC
coupled to a Thermo LTQ Orbitrap Velos mass-spectrometry.
Samples were loaded onto a 100-mm diameter column (length
100 mm) packed with 3 mm Reprosil Pur C18 AQ resin. Solvent A
and B were 0.1% formic acid in water and acetonitrile, respectively.
The gradient was 3% B to 40% B in 17 min followed by 40% B to 90%
B in 0.5 min, then 90% B for 2 min and ﬁnal re-equilibration for
10.5 min. The ﬂow rate was set to 500 nL/min The mass spectro-
meter was operated in positive ion mode using a spray voltage of
1.8 kV, and a capillary temperature of 200 °C. Data were acquired
in top-15, data-dependent acquisition mode using a collision vol-
tage of 30 V.
4.3. Protein identiﬁcation
Mass spectra were extracted, deconvolved and deisotoped
using Proteome Discoverer 1.4.1.14 (Thermo Fisher Scientiﬁc,
Waltham, MA) and searched against a concatenated database
(Homo sapiens, Mus musculus, UniprotKB/Swissprot) using Mascot
(Matrix Science, London, UK; version 1.4.1.14). Oxidation (Met),
carbamidomethylation (Cys) were speciﬁed as variable modiﬁca-
tions. Peptides were allowed maximum two trypsin missed clea-
vages with a mass tolerance of 710 ppm, and a fragment ion mass
tolerance of 70.8 Da. Search results were imported into Scaffold
(Proteome Software Inc., Portland, OR), and identiﬁcations were
conﬁrmed by X!Tandem (The GPM, v2010.12.01.1). Only proteins
with probabilities equal or higher than 99.0% were retained for
analysis (one or more peptide per protein contributing to a posi-
tive match). Computation of putative PPIs (manual and SAINTex-
press) were based on exclusive spectrum counts, as determined by
Scaffold.
4.4. Bioinformatics, pathway analysis and gene ontology analysis
A combination of an unsupervised probabilistic approach
(SAINTexpress, (Choi et al., 2012)) and a manual approach was
used to identify proteins potentially interacting with RBM45. For
each protein–protein interaction, SAINTexpress predicted an in-
dividual probability based on spectral counts and reported average
probabilities across all replicates (AvgP), average fold-change,
average spectral counts and a Bayesian False Discovery Rate
(BFDR) (Teo et al., 2014). Empty vector IPs were used as experi-
mental controls to provide a background list of proteins binding
non-speciﬁcally to the construct. The interactions provided by
SAINTexpress were ﬁltered for protein fold change equal or greaterthan 2, for proteins observed in at least 2 out of 3 replicates and
with an AvgP equal or greater than 0.7, as recommended (Choi
et al., 2012).
For manual elucidation of candidate PPIs, only proteins ob-
served in at least 2 out of 3 replicates were retained in RBM45 IPs.
Fold-change was calculated as the sum of exclusive spectral counts
across RBM45 replicates divided by the sum of the exclusive
spectral counts of that protein in the vector control replicates. Any
protein with a fold-change smaller than 2 was ﬁltered out.
PPIs with the highest degree of conﬁdence, e.g. valid across the
unsupervised and manual approaches were then analyzed using
Ingenuity Pathway Analysis software (IPAs, QIAGEN Redwood
City). The default IPA parameters were utilized along with Uniprot
identiﬁers for mapping proteins within IPA. The reference set for
analysis was the Ingenuity Knowledge Base. Direct and indirect
relationships were included but only from proteins that were ex-
perimentally observed. IPA mapped 127 out of 131 proteins to
known pathways. P-value and percent overlap were used to rank
potentially signiﬁcant pathways.
To identify biological processes associated with the list of
RBM45 interacting proteins, we performed enrichment analysis in
the Gene Ontology (GO) Biological Process domain using Cytos-
cape (Shannon et al., 2003) together with the ClueGo plugin
(Bindea et al., 2009). We performed enrichment analysis using the
right-sided hypergeometric test with Benjamini–Hochberg post-
hoc correction. GO terms were considered signiﬁcant at the
po0.001 level and the resultant signiﬁcant terms were visualized
in a network layout where GO Biological Process terms were vi-
sualized as color-coded circular nodes, with node size corre-
sponding to enrichment p value. The overlap of proteins associated
with any two Biological Process terms was evaluated using the
kappa statistic and nodes were connected where the κ value was
Z0.4 using edges, with edge thickness corresponding to kappa
score. We then took leading terms, those GO Biological Process
terms with the highest number of associated proteins, and visua-
lized these in a network layout where Biological Process terms
were connected by edges to their associated proteins. All ﬁnal
ﬁgures were assembled using Adobe Illustrator CS5 (Adobe Sys-
tems; San Jose, CA, USA).
4.5. Reciprocal immunoprecipitation
Cells were cultured and processed as described previously. In-
cell RNase treatment was performed as described in Li et al.
(2015). 500 mg total protein and 2 mg antibody was ﬁrst incubated
at 4 °C for 1 h, and the entire mixture was added to 15 ml Protein A/
G Agarose (Pierce) and rotated at 4° C for 3 h. The im-
munoprecipitates were washed 4 times and analyzed for im-
munoblot. The antibodies used for immunoprecipitations are as
follows: mouse monoclonal hnRNP-L antibody (Novus Biological
NB120-6106), rabbit monoclonal hnRNP-A1 antibody (Cell Sig-
naling 8443S), rabbit polyclonal Matrin-3 antibody (Abcam
ab70336), rabbit polyclonal RBM14 antibody (Proteintech 10196-
1-AP). IgG-IP control was performed using rabbit IgG (Sigma
I5006) and mouse IgG (Sigma I5381).
4.6. Immunoblot
Protein samples were mixed with 4 SDS loading buffer and
denatured by heating (95 °C for 5 min for regular IP samples and
95 °C for 20 min for crosslinking IP samples), resolved on the Bolt
4–12% Bis-Tris Plus Gel (Life Technologies), and transferred to
Immobilon-FL PVDF membrane (Millipore). The membranes were
blocked with Odyssey Blocking Buffer (LiCOR) for 1 h. The anti-
bodies were diluted in Odyssey Blocking Buffer with 0.1% Tween-
20. Primary antibody incubation was performed at room
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ondary antibody (LiCOR) incubation was performed at room
temperature for 1 h. The membranes were scanned using the
Odyssey CLx Infrared Imaging System (LiCOR). The primary anti-
bodies used for immunoblot are as follows: mouse monoclonal
FLAG M2 antibody (Sigma F3165, 1:5000), rabbit monoclonal
RBM45 C-terminal antibody (custom-made, 1:3000), rabbit
monoclonal hnRNP-A1 antibody (Cell Signaling 8443S, 1:3000),
mouse monoclonal hnRNP-L antibody (Novus Biological NB120-
6106, 1: 10,000), mouse monoclonal hnRNP-A2B1 antibody (Santa
Cruz sc-32316, 1:3000), rabbit monoclonal Matrin-3 antibody
(Abcam ab151714, 1:10,000), rabbit polyclonal RBM14 antibody
(Proteintech 10196-1-AP, 1:5000), rabbit polyclonal TDP-43 anti-
body (Proteintech 10782-2-AP, 1:3000), rabbit monoclonal GAPDH
antibody (Cell Signaling 2118S, 1:5000). The appropriate secondary
antibodies conjugated with LiCOR IRDye 800CW or IRDye 680RD
antibodies made in goat (1: 15,000) were used for immunoblot
experiments.
4.7. Immunocytochemistry
For immunocytochemistry, HEK293 cells were grown on
number 1.5 glass coverslips. Cells were washed with 1X PBS and
ﬁxed in 4% paraformaldehyde for 10 min. After ﬁxation and further
washing, cells were permeabilized by immersion in 1X PBS con-
taining 0.1% Triton X-100 for 15 min. After further washing, cells
were blocked by incubation in SuperBlock (Scytek) for 1 h. Sub-
sequently, primary antibody solutions were applied and allowed to
incubate for 2 h. Following primary antibody incubations, cover-
slips were washed four times in a 1:10 mixture of SuperBlock:1X
PBS. Secondary antibodies were applied following these washes,
allowed to incubate for 1 h, and washed four times as above. Cell
nuclei were visualized by staining with a 300 nM DAPI solution for
10 min followed by washing with 1X PBS. Coverslips were
mounted on glass slides using 2,2′-thiodiethanol (TDE) according
to the method of Staudt et al. (2007). In brief, coverslips were
immersed in a series of increasing concentrations of TDE (10%,
25%, 50%, and 97%). The ﬁnal TDE solution has a refractive index of
1.518 to match that of the immersion oil used in imaging the
slides.
The primary antibodies used for immunoﬂuorescence were as
follows: rabbit monoclonal RBM45 C-terminal antibody (custom-
made, 1:250), rabbit monoclonal hnRNP-A1 antibody (Cell Sig-
naling 8443S, 1:800), mouse monoclonal hnRNP-A2B1 antibody
(Santa Cruz sc-32316, 1:250), rabbit polyclonal hnRNP-A3 antibody
(Sigma AV41195, 1:200), mouse monoclonal hnRNP-L antibody
(Novus Biological NB120-6106, 1:1000), rabbit monoclonal Matrin-
3 antibody (Abcam ab151714, 1:500), mouse monoclonal G3BP
antibody (BD Transduction Laboratories, 1:250), mouse mono-
clonal SMN antibody (Sigma S2944, 1:400), and mouse mono-
clonal FLAG M2 antibody (Sigma F3165, 1:1000). The secondary
antibodies used for immunoﬂuorescence were goat-anti-Cy2
(rabbit) and goat-anti-Cy5 (Mouse) (Millipore, 1:1000 for both).
4.8. Microscopy, digital deconvolution, and co-localization analysis
An Observer Z1 microscope (Zeiss) was used for all image ac-
quisitions using a 63 (1.4 NA) objective and LED light source.
Images were acquired as three-dimensional stacks with a Z sam-
pling interval of 0.240 mm. Images were shading corrected and
background subtracted. Following acquisition, images were de-
convolved using Huygens Essential deconvolution software (SVI).
Deconvolution and chromatic shift correction were performed
using a measured PSF obtained by volume imaging of 200 mm
ﬂuorescent beads (Life Technologies) together with the Huygens
Essential PSF Distiller application. Deconvolution was performedusing the software's classic maximum likelihood estimation algo-
rithm. Deconvolved images were used to analyze the co-localiza-
tion of RBM45 and selected RBM45 interacting proteins identiﬁed
by IP–MS. Co-localization analysis was performed using ImageJ
(Schneider et al., 2012) in conjunction with the JaCoP plugin (Bolte
and Cordelieres, 2006). Images were automatically thresholded for
analysis using the method of Costes et al. (2004) and the M1 and
M2 overlap coefﬁcients (Bolte and Cordelieres, 2006) and intensity
correlation quotient (ICQ) (Li et al., 2004) were calculated. Statis-
tical signiﬁcance of the ICQ was evaluated using the normal ap-
proximation of the sign test as in (Li et al., 2004).Author contributions
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